TriSalus CEO Sells $79K in Stock to Settle RSU Taxes; Company Posts Revenue Gains but Remains Loss-Making
TriSalus Life Sciences CEO Mary T. Szela disposed of 20,302 shares across two trades in March to satisfy tax obligations tied to vesting restricted stock units. The sales, executed on March 11 and March 17, raised $79,382 in aggregate. The moves coincide with mixed corporate results: meaningful revenue growth in Q4 2025 and fiscal 2025, an improved…